19 projects, 18 succeeded, all 6 GPCR targets hit! Domestic AI drug discovery breaks through the technical ceiling again

What happened: Molecular Heart released a technical report on its AI protein de novo design platform MMDesign, covering 19 design projects across 18 targets in nanobody (VHH) and macrocyclic peptide modalities. Key numbers: 18 of 19 projects Why it matters: The report frames MMDesign as moving from technical breakthrough to systematic validation, with the same generate, filter, verify workflow repeated across targets and modalities, including 5 GPCR targets with no catalogued therapeutic antibody precedent. Note: The source content is in Chinese; this summary translates the stated facts.

Molecular Heart released a technical report on its AI protein de novo design platform MMDesign, covering 19 design projects across 18 targets in nanobody (VHH) and macrocyclic peptide modalities.

The report frames MMDesign as moving from technical breakthrough to systematic validation, with the same generate, filter, verify workflow repeated across targets and modalities, including 5 GPCR targets with no catalogued therapeutic antibody precedent. Note: The source content is in Chinese; this summary translates the stated facts.